Strong Buy CAPR by Sep 1, 2025.

CAPR surged **+20% post-earnings** to \~$14.36, reaffirming its resilience despite broader market volatility. This update follows my previous DD post, which was removed but is now eligible for reposting. Despite the move, **CAPR remains significantly undervalued** given its upcoming **FDA decision (PDUFA: Aug 31, 2025)**, its **revenue share with Nippon Shinyaku (30-50%)**, and **a likely $1.2M per patient per year price tag** for Deramiocel. **Deramiocel U.S. Pricing – Now Expected at $1.2M Per Year** 📌 **From Capricor’s March 2025 Investor …